Solgar Glucosamine Chondroitin (Nestle) – packaging error (2023)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Solgar, Triple Strength, Shellfish -Free, Glucosamine Chondroitin MSM, 120 Tablets per bottle. Glass Bottle, 12 per Case, Store at room temperature . Product Number -1319
Brand
Nestle Product Technology Center - Nestle Health Science
Lot Codes / Batch Numbers
Lot/Unit Numbers: 3250UM0704 UPC Codes: 041260351211
Products Sold
Lot/Unit Numbers: 3250UM0704 UPC Codes: 041260351211
Nestle Product Technology Center - Nestle Health Science is recalling Solgar, Triple Strength, Shellfish -Free, Glucosamine Chondroitin MSM, 120 Tablets per bottle. Glas due to Nestle Health Science has initiated a recall of Solgar Glucosamine Chondroitin, 120 Tablets, in Glass bottle, 12 bottles per case because of error dur. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Nestle Health Science has initiated a recall of Solgar Glucosamine Chondroitin, 120 Tablets, in Glass bottle, 12 bottles per case because of error during packaging in which a A Megasorb B-Complex product was filled into bottles labeled as Glucosamine_Chondroitin MSM.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticeDistribution
As reported by FDA
IN, NV, NY, PA, TN, TX
Page updated: Jan 6, 2026